Navigation Links
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

se events included fatigue, hand/foot syndrome and skin rash.

The lead investigator for this study is Joan Schiller, MD, professor and chief of the hematology/oncology division at the University of Texas Southwestern and Andrea L. Simmons distinguished chair in cancer research, Dallas, TX. (abstract #8014).

Thyroid Cancer

A Phase 2 Study of Sorafenib in Metastatic Thyroid Carcinoma

Findings from this single-arm Phase 2 study showed that treatment with Nexavar resulted in meaningful anti-tumor activity in the majority of patients with encouraging overall clinical benefit (disease stabilization and partial responses) in patients with advanced thyroid cancer. In the study, Nexavar was well-tolerated; the most common treatment-related adverse events included fatigue, rash, diarrhea, palmer-plantar erythema, musculoskeletal pain and weight loss. Patients enrolled in this study had been diagnosed with metastatic, iodine-refractory, unresectable or locally-advanced thyroid cancer.

The lead investigator for this study is Marcia S. Brose, MD, PhD, assistant professor, director of cancer genetics laboratory, University of Pennsylvania Health System, Philadelphia, PA. (abstract #6026).

Gastrointestinal Stromal Tumors

Activity of Sorafenib in Patients with Imatinib and Sunitinib-Resistant Gastrointestinal Stromal Tumors (GIST): A Phase 2 Trial of the University of Chicago Phase 2 Consortium

Findings from this single-arm Phase 2 study suggest that Nexavar is active and well tolerated in patients with Gleevec or Gleevec and Sutent resistant GIST. The most common treatment-emergent adverse events included hand-foot syndrome, hypertension, rash and diarrhea.

The lead investigator for this study is Lauren Wiebe, MD, fellow, University of Chicago, Chicago, IL. (abstract #10502).

Gastric/GEJ

A Phase 2 Study: Combination of Sorafenib with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Unres
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
2. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
3. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
10. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
(Date:7/24/2014)... , July 24, 2014  The American ... is supporting its mission to help address audit ... and exclusive agreement to be the information technology ... As the leading provider of billing and business ... unmatched HME industry expertise to support this important ...
(Date:7/24/2014)... , July 24, 2014  In any given hospital ... 25 patients has at least one hospital-acquired infection, according ... more, many of these infections prove fatal. And as ... alarming number of patient deaths per year, infection control ... Consequently, a stronger emphasis is being ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
... Computer Company (PCC) – a Vermont pediatric software developer ... updated 5010 transaction standard for electronic claims and claims ... among its payers. An ICD-10/5010 Readiness Survey ... Systems Society (HIMSS), indicates an estimated 1/3 of health ...
... Masimo (NASDAQ: MASI ) announced today that it ... 2, 2011, after the market closes on May 3, 2011. ... 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by ... Raad, Executive Vice President and Chief Financial Officer. A ...
Cached Medicine Technology:PCC Frustrated with Payers' Lack of 5010 Readiness 2Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 2011 2Masimo to Report First Quarter 2011 Financial Results After Market Close on May 3, 2011 3
(Date:7/25/2014)... Washington, DC (PRWEB) July 25, 2014 ... against some health plans for providing inadequate access to ... serious threats to the health and safety of beneficiaries ... of drug coverage determinations, and CMS is taking quick ... 5, the Atlantic Information Services webinar, “Avoiding Costly ...
(Date:7/25/2014)... iTanSmart is a patented iOS suntan ... provides a tailored approach to eliminating the guesswork from ... skin damage. In his review, Eaton had positive things ... iTanSmart. , Eaton begins his commentary ... organized’ and ‘great alternative’ to its related Android competitor. ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer ... casual party dresses . According to the company’s ... now offered at discounted prices, up to 59% off. ... August 04. , Most of the casual party ... market. They are popular for special designs, delicate craftsmanship ...
(Date:7/24/2014)... For rats bearing human breast tumors, exposure to ... the breast cancer drug tamoxifen, according to data published ... American Association for Cancer Research. The negative effects of ... giving rats a melatonin supplement during the night. , ... with hormone receptor-positive breast cancer," said Steven M. Hill, ...
Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
... new analysis, it is better to give radiation therapy before ... well as surgery can reduce the risk of recurrence. Generally ... In Scandinavia and the Netherlands, the therapy is given before ... until afterwards.// ,An analysis of 8000 patients, led ...
... The diagnosis and treatment of epilepsy is often handled ... per cent of UK epilepsy patients not receiving appropriate ... epilepsy each year, and of these, about one-third can ... from the Institute of Neurology at University College London ...
... temperatures can lead to heat exhaustion and eventually to ... the temperature rises into the thirties. By the time ... ,Heat exhaustion refers to overheating of the ... rare cases, salt depletion. People who suffer from heat ...
... by cancer patients undergoing high-dose chemotherapy could be eased ... drugs used to fight cancer can prove extremely debilitating ... various anti-emetic drugs to lessen the reaction, but in ... a possible extra help. ,Acupuncture involves the insertion of ...
... Patients' experience of illness is being collected on a database ... ingredient in medical research is the patient's voice. It is ... researchers could learn a lot from the patient's ideas, beliefs ... too - showing they're not alone, and giving them vital ...
... able to treat the neurological problems that are common ... suffer from kidney failure, which is usually caused by ... leads to neurological complications like fatigue, apathy, emotional instability ... at the University of California at Irvine have learned ...
Cached Medicine News:
... The Bledsoe Lever Lock Knee Brace ... extension lock of the arthroscopic ACL ... allow motion for rehabilitation or passive ... locked "rigidly" in full extension for ...
The Bledsoe Basic Knee Brace offers a broad range of features that are unmatched by any other brace in its price range. Application of this brace is the easiest of any brace on the market....
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
Medicine Products: